No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US Stock MarketDetailed Quotes
BIO Bio-Rad Laboratories
- 304.150
- +8.630+2.92%
Close Jul 12 16:00 ET
- 304.270
- +0.120+0.04%
Post 16:29 ET
8.68BMarket Cap-28451P/E (TTM)
304.440High297.540Low301.85KVolume297.570Open295.520Pre Close91.58MTurnover1.51%Turnover RatioLossP/E (Static)28.52MShares431.79052wk High0.96P/B6.07BFloat Cap261.59052wk Low--Dividend TTM19.97MShs Float832.700Historical High--Div YieldTTM2.34%Amplitude9.438Historical Low303.384Avg Price1Lot Size
Full Hours
- 5D
- Daily
- Weekly
- Monthly
- 1Q
- 1Y
Trade Overview
Unit: --
Capital Trend
IntradayDayWeekMonth
No Data
News
Citi Upgrades Illumina, Quest, Agilent to Buy, Downgrades Avantor
S&P 500 Ends First Half Shy Of All-Time Highs. Here Are The Leaders And Laggards — And 5 Stocks That Could Outperform In Next 6 Months
The stock market is up solidly this year, thanks to expectations of rate cuts by the Federal Reserve amid easing inflationary pressure, strong corporate earnings and optimism over the potential of art
RBC Trims Price Target on Bio-Rad Laboratories to $402 From $414, Keeps Outperform Rating
Bio-Rad Laboratories (BIO) has an average investment rating of outperform among analysts polled by Capital IQ, with price targets ranging from $300 to $430.
Express News | Bio Rad Laboratories Inc : RBC Cuts Target Price to $402 From $414
Top Gap Ups and Downs on Monday: AVGO, DELL, SONY and More
Gaps can show signals that something important has happened to the fundamental or the psychology of traders that accompanies this market movement.
Bio-Rad Laboratories on Pace for Largest Percent Increase Since December 2023 -- Data Talk
Bio-Rad Laboratories, Inc. Class A (BIO) is currently at $298.34, up $16.08 or 5.7% --Would be highest close since May 15, 2024, when it closed at $300.97 --On pace for largest percent increase sinc
Comments
Despite a superior revenue outlook, the company isn't trading at a higher P/S due to potential risks like not meeting analysts' revenue projections in tough industry conditions. Investors anticipate future revenue volatility.
Take Care Before Diving Into The Deep End On Bio-Rad Laboratories, Inc. (NYSE:BIO)Bio-Rad's unstable profits and stale growth over the past three years are worrying. Despite a rise in stocks, long-term performance lacks strength. If fundamentals signal sustainable growth, the current sell-off could be a chance.
Here are the top gap ups and downs for the stocks with a market cap above $5 billion after the previous market closed (gaps range from large to small):
Gap Ups
1. $Live Nation Entertainment(LYV.US$ - up 9.3%
2. $BILL Holdings(BILL.US$ - up 8.7%
3. $Coinbase(COIN.US$ - up 6.5%
4. $DraftKings(DKNG.US$ - up 6.2%
5. $Apellis Pharmaceuticals(APLS.US$ - up 5.3%
6. $Reinsurance Group of America(RGA.US$ - up 3.9%
7. $Equinor(EQNR.US$ - up 3.7...
Gap Ups
1. $Live Nation Entertainment(LYV.US$ - up 9.3%
2. $BILL Holdings(BILL.US$ - up 8.7%
3. $Coinbase(COIN.US$ - up 6.5%
4. $DraftKings(DKNG.US$ - up 6.2%
5. $Apellis Pharmaceuticals(APLS.US$ - up 5.3%
6. $Reinsurance Group of America(RGA.US$ - up 3.9%
7. $Equinor(EQNR.US$ - up 3.7...
+16
16
2
$Tesla(TSLA.US$ what is tour curren car and next car?
$Bio-Rad Laboratories(BIO.US$ $XPeng(XPEV.US$ $Li Auto(LI.US$
$Bio-Rad Laboratories(BIO.US$ $XPeng(XPEV.US$ $Li Auto(LI.US$
Read more
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
%Chg